TRPV4 as a Novel Regulator of Ferroptosis in Colon Adenocarcinoma: Implications for Prognosis and Therapeutic Targeting
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Transient receptor potential vanilloid 4 (TRPV4) is elevated in colon adenocarcinoma (COAD), promoting tumor progression via the ferroptosis pathway. Targeting TRPV4 may offer a new therapeutic strategy for COAD patients.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Colon adenocarcinoma (COAD) is a major cause of cancer mortality globally.
- Transient receptor potential vanilloid 4 (TRPV4) channels are implicated in various cancers, including COAD.
Purpose Of The Study
- To investigate the role of TRPV4 in colon adenocarcinoma (COAD).
- To elucidate the mechanism by which TRPV4 influences COAD, specifically through the ferroptosis pathway.
Main Methods
- Utilized The Cancer Genome Atlas (TCGA) for gene expression and clinical data from 647 COAD and 51 normal samples.
- Performed differential expression, survival, and Cox regression analyses for prognostic significance.
- Conducted bioinformatics analyses (PPI, GO, KEGG) and in vitro experiments (siRNA knockdown, HE staining, immunofluorescence) in HT-29 and SW480 cell lines.
Main Results
- TRPV4 expression was significantly higher in COAD tissues (p < 0.05) with high diagnostic accuracy (AUC = 0.848).
- Elevated TRPV4 correlated with poorer overall and disease-specific survival, especially in older patients and stage II COAD.
- TRPV4 knockdown reduced cell viability and key ferroptosis/proliferation markers (SLC3A2, GPX4, KI67, SRC, COL1); ferroptosis inhibitor FER-1 did not rescue viability.
Conclusions
- TRPV4 promotes COAD cell survival by regulating the ferroptosis pathway, impacting ferroptosis and proliferation markers.
- TRPV4 is an independent prognostic factor in COAD, suggesting its potential as a therapeutic target.
- Further research into TRPV4's role in other cancers and therapeutic development is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
